# TABLE 4

# SUMMARY

Submitter's name: Address:

Phone:

Guangzhou Wondfo Biotech Co., Ltd. South China University of Technology Guangzhou, P.R. China 510641 012-86-20-32296069

Joe Shia LSI International Inc. 504 East Diamond Ave., Suite F Gaithersburg, MD 20878 Telephone: 240-505-7880 Fax: 301-916-6231

Date the summary was prepared:

Name of the device: Trade or proprietary name: Common or usual name:

December 13, 2010

Cannabinoids Urine Test   
Cannabinoids Urine Test   
Immunochromatographic test for the qualitative detection   
of Cannabinoids

Classification: Class II medical device with the product codes with Code of Federal Regulation references: 1

Product Code LDJ

CFR# 862.3870

The legally marketed device to which we are claiming equivalence [807.92(a)(3)]: Acon Laboratories, Inc. One Step Drug Screen Test Card, K020771.

Description of the device:

Assay Principle: Immunochromatographic assay for Cannabinoids urine test using a lateral flow system for the qualitative detection of Cannabinoids in human urine. Each assay uses a monoclonal antibody-dye congugate from mouse against drug with gold chloride and fixed drug-protein conjugate and anti-mouse IgG polyclonal antibody in membrane.

Intended use of the device:

The Cannabinoids Urine Test is intended for the qualitative determination of Cannabinoids in human urine. Thev are intended for healthcare professional use and over the counter use.

Summarv of the technological characteristics of our device compared to the predicate device:

The Wondfo Biotech Co., Ltd. Cannabinoids have similar technological characteristics and performance to the predicate and are equivalent.

Guangzhou Wondfo Biotech Co., LTD. c/o Joe Shia, LSl International Inc.   
504 East Diamond Ave.   
Suite F   
Gaithersburg, MD 20877

Re: k110182 Trade Name: Wondfo Cannabinoids Urine Test Regulation Number: 21 CFR $\ S 8 6 2 . 3 8 7 0$ Regulation Name: Cannabinoid Test System Regulatory Class: Class II Product Codes: LDJ Dated: May 16, 2011 Received: May 19, 2011

Dear Mr. Shia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of-Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Gc.

:

Cousthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

Device Name: Wondfo Cannabinoids Urine Test

Indications for Use:

Wondfo Cannabinoids Urine Test is an immunochromatographic assay for the qualitative determination of 50ng/mL of Cannabinoids. It is intended for prescription use and over the counter use.

T obtain a conformed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and pnal un hou e w   u pculay h e result is positive.

# Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/fbbbc62a11fbd60d7f824c6c88d21229f6b4cd2865bc82ff1b6240eb5c0134c4.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

5101k) K110182